January 17, 2021

ASCO GI

Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with previously treated CCA and an (IDH1) mutation

December 7, 2020

ASH Annual Meeting 2020

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML

December 7, 2020

ASH Annual Meeting 2020

AGILE: Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with AML & IDH Mutation

December 7, 2020

ASH Annual Meeting 2020

Longitudinal molecular profiling in patients with IDH1-mutant newly diagnosed AML treated with ivosidenib

December 6, 2020

ASH Annual Meeting 2020

Molecular characterization of clinical response and relapse in patients with IDH1-mutant newly diagnosed AML treated with ivosidenib & azacitidine

December 6, 2020

ASH Annual Meeting 2020

Phase I Study of the IDH2 inhibitor enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms following hematopoietic cell transplantation

July 22, 2020

Cholangiocarcinoma Foundation Annual Conference 2020

Health-related quality of life in patients treated with ivosidenib for mutant-IDH1 cholangiocarcinoma: Results from ClarIDHy

June 22, 2020

AACR Annual Meeting 2020

Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment

June 22, 2020

AACR Annual Meeting 2020

MAT2A inhibitor AG-270 combines with both taxanes and gemcitabine to yield enhanced antitumor activity in patient-derived xenograft models

June 12, 2020

EHA Annual Congress 2020

Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib, with the BCL2-inhibitor venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

June 12, 2020

EHA Annual Congress 2020

Ivosidenib improves overall survival relative to standard therapies in relapsed or refractory mutant IDH1 AML

June 12, 2020

EHA Annual Congress 2020

Ivosidenib (IVO) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS)

June 12, 2020

EHA Annual Congress 2020

Pharmacodynamic evaluation of IVO combined with intensive induction and consolidation chemotherapy in patients with newly diagnosed IDH1/2-mutant AML

June 12, 2020

EHA Annual Congress 2020

Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)

May 29, 2020

ASCO Annual Meeting 2020

Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients with recurrent/progressive glioma

May 29, 2020

ASCO Annual Meeting 2020

Phase Ib/II Study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies

May 29, 2020

ASCO Annual Meeting 2020

INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881)

May 29, 2020

ASCO Annual Meeting 2020

IDH1 mutation detection in plasma ctDNA and association with clinical response in patients with advanced ICC from the phase 3 ClarIDHy study

May 29, 2020

ASCO Annual Meeting 2020

Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)

December 9, 2019

ASH Annual Meeting 2019

Complex polyclonal resistance mechanisms to ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML revealed by single-cell sequencing analyses

December 9, 2019

ASH Annual Meeting 2019

Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study

December 9, 2019

ASH Annual Meeting 2019

Molecular mechanisms mediating relapse following ivosidenib monotherapy in patients with IDH1-mutant relapsed or refractory AML

December 8, 2019

ASH Annual Meeting 2019

High rate of IDH1 mutation clearance and MRD negativity in patients with IDH1-mutant newly diagnosed AML treated with ivosidenib (AG-120) & azacitidine

December 8, 2019

ASH Annual Meeting 2019

AGILE: Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib with azacitidine in adults with previously untreated AML with an IDH1 mutation

November 22, 2019

SNO Annual Meeting 2019

A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma

October 27, 2019

AACR-NCI-EORTC 2019

A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion

October 27, 2019

AACR-NCI-EORTC 2019

Mitotic defects induced by MAT2A inhibitors guide translational drug combination strategies with AG-270 and taxanes

September 30, 2019

ESMO Congress 2019

ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced CCA with an IDH1 mutation

June 15, 2019

EHA Annual Congress 2019

Ivosidenib (AG-120) induces durable remissions and transfusion independence in patients with IDH1-mutant relapsed/refractory MDS in a phase 1 dose escalation and expansion study

June 3, 2019

ASCO Annual Meeting 2019

Mutant IDH1 inhibitor ivosidenib (AG-120) in combination with azacitidine for newly diagnosed AML

June 3, 2019

ASCO Annual Meeting 2019

Phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: Results from Cohort 1

June 3, 2019

ASCO Annual Meeting 2019

Ivosidenib (AG-120) in IDH1-mutant newly diagnosed acute myeloid leukemia: Updated results from a phase 1 study

April 2, 2019

AACR Annual Meeting 2019

Detection of IDH1 mutations in plasma cell-free circulating tumor DNA (ctDNA) from patients with cholangiocarcinoma

April 2, 2019

AACR Annual Meeting 2019

Inhibition of mutant IDH enzymes reduces production of 2-HG but does not restore wild-type IDH activity in vitro or in vivo

April 2, 2019

AACR Annual Meeting 2019

IDH1-R132H tumor cells are not robustly sensitive to PARP inhibition in a 2-HG–dependent manner

April 1, 2019

AACR Annual Meeting 2019

Targeting MAT2A in CDKN2A/MTAP-deleted Cancers

March 18, 2019

Keystone Meeting 2019

Targeting MAT2A in MTAP-deleted Cancers

February 25, 2019

Acute Leukemias XVII

Safety and clinical activity of mutant IDH1 inhibitor ivosidenib (AG-120) in combination with azacitidine for newly diagnosed AML

More from Servier

Research & Development

We invest in the research and development of innovative medicines, all designed with the goal to best address the unmet needs of patients. 

Learn More

Clinical Trials

We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.

Learn More

Medicines

Servier Pharmaceuticals' medicines change the lives of the patients we serve. Currently, within the United States, oncology treatment and care are our immediate focus.

Learn More